Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.59 |
| ▸ | TDP2 | O95551 | 2/20 | 0.56 |
| ▸ | PNMT | P11086 | 10/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040944 | 1.00 | CMA1 (0.59) | CMA1AHRTDP2PNMTMETAP1 | |
| SCHEMBL1852665 | 0.92 | CMA1 (0.59) | CMA1AHRTDP2PNMTMETAP1 | |
| SCHEMBL1264716 | 0.83 | PARP10 (0.59) | CMA1AHRTDP2PNMTMETAP1 | |
| SCHEMBL1263806 | 0.79 | ASIC3 (0.55) | CMA1AHRTDP2PNMTMETAP1 | |
| SCHEMBL23561875 | 0.77 | TDP2 (0.44) | CMA1AHRTDP2 | |
| SCHEMBL31254528 | 0.77 | PARP1 (0.43) | CMA1AHRTDP2PARP10PARP1 | |
| SCHEMBL14368233 | 0.77 | METAP1 (0.44) | CMA1AHRTDP2METAP1PARP10 | |
| SCHEMBL30839539 | 0.77 | CA9 (0.44) | CMA1AHRTDP2PARP1 | |
| SCHEMBL21247645 | 0.77 | CA9 (0.44) | CMA1AHRTDP2PARP1 | |
| SCHEMBL29584808 | 0.74 | AHR (1.00) | CMA1AHRTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619407-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | Curadev Pharma Ltd (GB) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025034849-A1 | FUSED PYRIDAZINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2014043296-A1 | AMINOISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014043296-A1 | AMINOISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | MERCK SHARP & DOHME CORP. | 2011-06-09 | — | — | US | disclosed |
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | MERCK SHARP & DOHME CORP. | 2011-06-09 | — | — | US | disclosed |
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | MERCK SHARP & DOHME CORP. | 2011-06-09 | — | — | US | disclosed |
| US-7713994-B2 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2010017048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE AND ISOQUINOLINEDIONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | CMA1 544/4885AHR 89/4885TDP2 3493/4885 |
| US-20110136842-A1 | Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers | CACNA1D, TRPV1, CACNA1S | CMA1 758/4885AHR 571/4885TDP2 3450/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | CMA1 491/4885AHR 271/4885TDP2 3949/4885 |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | CMA1 483/4885AHR 83/4885TDP2 3905/4885 |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | CMA1 3659/4885AHR 1357/4885TDP2 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.